Metformin: updated guidance and pleiotropic potential


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Metformin is one of the most prescribed and effective anti-diabetic drugs in the world, which provides additional benefits for patients with type 2 diabetes for the control of certain risk factors for cardiovascular diseases, reduce cardiovascular morbidity and mortality, reduce the risk of some forms of cancer. There is increasing evidence of a variety of biological pleiotropic effects of metformin (antioxidative, hypolipidemic, anti-inflammatory, anorectic effect, anti-atherosclerotic, antiproliferative), the clinical significance of which requires further study.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Inna Druk

Omsk state medical university

Email: drukinna@yandex.ru
MD, associate professor, Department of internal diseases and family medicine

Yelena Ryapolova

Omsk state medical university

Email: osma-genpract@yandex.ru
PhD, assistant professor, Department of internal diseases and family medicine

Әдебиет тізімі

  1. Rios J.L., Francini F., Schinella G.R. Natural products for the treatment of type 2 diabetes mellitus. Planta Med. 2015;81(12-131:975-94.
  2. Bailey C.J., Day C. Metformin: its botanical background. Practical Diabetes International. 2004;21(3):115-7.
  3. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. 7-е изд. Москва, 2015. 112 с. [Algorithms of specialized medical care for patients with diabetes. Ed. by I.I. Dedov, M.V. Shestakova. 7th edition. Moscow, 2015. 112 p. (in Russian)]
  4. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(Suppl 1):S14-80. Goodman M., Liu Z., Zhu P., Li Ji. AMPK activators as a drug for diabetes, cancer and cardiovascular disease. Pharm. Regul. Aff. 2014;3(2):118
  5. Mazza A., Fruci B., Garinis G.A., Giuliano S., Malaguarnera R., Belfiore A. The role of metformin in the management of NAFLD. Exp. Diabetes Res. 2012;2012:716404
  6. Buse J.B., DeFronzo R.A., Rosenstock J., Kim T., Burns C., Skare Sh., Baron A., Finema M. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39(2):198-20
  7. Vardarli I., Arndt E., Deacon C.F., Holst J.J., Nauck M.A. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. Diabetes. 2014;63(2):663-74
  8. Mulherin A.J., Oh A.H., Kim H., Grieco A., Lauffer L.M., Brubaker P.L. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology. 2011;152(12):4610-9
  9. Bailey C.J., Turner R.C. Metformin. N. Engl. J. Med. 1996;334:574-9.
  10. Lee H., Ko G. Effect of metformin on metabolic improvement and gut microbiota. Appl. Environ. Microbiol. 2014;80:5935-43.
  11. Hajjar J., Habra M.A., Naing A. Metformin: an old drug with new potential. Expert. Opin. Investig. Drugs. 2013;22(12):1511-7.
  12. Nascimbeni F., Aron-Wisnewsky J., Pais R., Tordjman J., Poitou Ch., Charlotte F., Bedossa P., Poynard Th., Clément K., Ratziu V. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastro. 2016;3(1):e000075.
  13. Hassan M.M., Curley S.A., Li D., Kaseb A., Davila M., Abdalla E.K, Javle M., Dalia M.M., Lozano R.D, Abbruzzese J.L., Vauthey J.-N. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010;116(8):1938-46.
  14. Ferrannini E., DeFronzo R.A. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur. Heart J. 2015;3:2288-96.
  15. Kumar R., Kerins D.M., Walther T. Cardiovascular safety of anti-diabetic drugs. E.H.J. Cardiovasc. Pharmacother. 2016;2:32-43.
  16. Hemmingsen B., Schroll J.B., Wetterslev J., Gluud C., Vaag A., Sonne D.P., Lundstrom L.H., Almdal T. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open. 2014;2:E162-E175.
  17. Chang Sh.-H., Wu L.-Sh., Chiou M.-J., Liu J.-R., Yu K.-H., Kuo Ch.-F., Wen M.-Sh., Chen W.-J., Yeh Y.-H., See L.-Ch. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13(123).
  18. Vasamsetti S.B., Karnewar S., Kanugula A.K., Thatipalli A.R., Kumar J.M., Kotamraju S. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes. 2015;64:2028-41.
  19. Hajjar J., Habra M.A., Naing A. Metformin: an old drug with new potential. Expert Opin. Investig. Drugs. 2013;22(12):1511-7.
  20. Marycz K., Tomaszewski K.A., Kornicka K., Henry B.M., Wronski S., Tarasiuk J., Maredziak M. Metformin decreases reactive oxygen species, enhances osteogenic properties of adipose-derivedmultipotent mesenchymal stem cells in vitro, and increases bone density in vivo. Oxid. Med. Cell Longev. 2016;2016:9785890.
  21. Shi Q., Liu S., Fonseca V., Shi L. The effect of metformin exposure on neurodegenerative disease among elder adult veterans with diabetes mellitus. New Orleans, LA. ADA 2016 Scientific Sessions. 2016; Abstract 72-OR/72.
  22. Lin H.-Ch., Stein J.D., Nan B., Childers D., Newman-Casey P.A., Thompson D.A., Richards J.E. Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus. JAMA Ophthalmol. 2015;133(8):915-23.
  23. Liu Q., Li S., Quan H., Li J. Vitamin B12 status in metformin treated patients: systematic review. PLoS One. 2014;9(6):e100379.
  24. Zdilla M.J. Metformin with either histamine H2-receptor antagonists or proton pump inhibitors: a polypharmacy recipe for neuropathy via vitamin B12 depletion. Clin. Diabetes. 2015;33(2):90-5.
  25. Salpeter S.R., Greyber E., Pasternak G.A., Salpeter Posthumous E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2010;20(1):CD002967.
  26. Chang C.H., Sakaguchi M., Dolin P. Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan. Pharmacoepidemiol. Drug Saf. 2016. doi: 10.1002/pds.4030. [Epub ahead of print]
  27. Hloch O., Charvat J., Masopust J., Havlin J. Lactic acidosis in medical ICU - the role of diabetes mellitus and metformin. Neuro. Endocrinol. Lett. 2012;33(8):792-5.
  28. Roussel R., Travert F., Pasquet B., Wilson P.W., Smith S.C.Jr, Goto S., Ravaud P., Marre M., Porath A., Bhatt D.L., Steg P.G. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch. Intern. Med. 2010;170:1892-9.
  29. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
  30. Herrero G.H., De Arriba V.C., Parra B.M., Sarasa A. M. Nephrotoxicity due to iodine contrasts in computerized tomography studies of diabetic outpatients on metformin. An. Sist. Sanit. Navar. 2013;36:197-201.
  31. Manual on Contrast Media v10.1 - American College of Radiology. Available at: http://www.acr.org/quality-safety/resources/ contrast-manual. Accessed December 7, 2015.
  32. Shah A.D., McHargue C., Yee J., Rushakoff R.J. Intravenous contrast in patients with diabetes on metformin new common sense guidelines. Endocr. Pract. 2016;22(4):502-5.
  33. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC).E.H.J. doi: 10.1093/eurheartj/ehw128.
  34. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (4-й пересмотр). Сердечная недостаточность. 2013;7(81):379-472. [National recommendations on the diagnosis and treatment of chronic heart failure (4th revision). Heart failure. 2013;7(81):379-472 (in Russian)]
  35. Diabetes prevention program research group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35:731-7.
  36. Desilets A.R., Dhakal-Karki S., Dunican K.C. Role of metformin for weight management in patients without type 2 diabetes. Ann. Pharmacother. 2008;42:817-26.
  37. Seifarth C., Schehler B., Schneider H.J. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp. Clin. Endocrinol. Diabetes. 2013;121:27-31.
  38. Cassar S., Teede H J., Moran L.J., Joham A.E., Harrison C.L., Strauss B.J., Stepto N.K. Polycystic ovary syndrome and anti-Mullerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins. Clin. Endocrinol. 2014;81:899-906.
  39. Carvajal R., Rosas C., Kohan K., Gabler F., Vantman D., Romero C., Vega M. Metformin augments the levels of molecules that regulate the expression of the insulin-dependent glucose transporter GLUT4 in the endometria of hyperinsulinemic PCOS patients. Hum. Reprod. 2013;28(8):2235-44.
  40. Badr D., Kurban M., Abbas O. Metformin in dermatology: an overview. J. Eur. Acad. Dermatol. Venereol. 2013;27(11):1329-35.
  41. Nieuwenhuis-Ruifrok A.E., Kuchenbecker W.K., Hoek A., Middleton P., Norman R.J. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum. Reprod. Update. 2009;15:57-68.
  42. Glintborg D., Altinok M.L., Mumm H., Hermann A.P., Ravn P., Andersen M. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2014;99:2584-91.
  43. Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R., Welt C.K. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013;98:4565-92.
  44. EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1 121-40.
  45. Диагностика и лечение неалкогольной жировой болезни печени. Методические рекомендации для врачей РОПИП. Под ред. акад. В.Т. Ивашкина. Москва, 2015. 38 с. [Diagnosis and treatment of nonalcoholic fatty liver disease. Methodical recommendations for doctors ROPIP. Ed. V.T. Ivashkina. Moscow, 201 5. 38 р. (in Russian)]
  46. Zhang X., Harmsen W.S., Mettler T.A., Kim W.R., Roberts R.O., Therneau T.M., Roberts L.R., Chaiteerakij R. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology (Baltimore, MD). 2014;60:2008-16.
  47. Donadon V., Balbi M., Mas M.D., Casarin P., Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010;30:750-8.
  48. Singh S., Singh P.P., Singh A.G., Murad M.N., McWilliams R.R., Chari S.T. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am. J. Gastroenterol. 2013;108:881-91.
  49. Chen H.P., Shieh J.J., Chang C.C., Chen T.T., Lin J.T., Wu M.S., Lin J.H., Wu C.Y. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013;62:606-1 5.
  50. Papanagnou P., Stivarou Th., Tsironi M. Unexploited antineoplastic effects of commercially available anti-diabetic drugs. Pharmaceuticals (Basel). 2016;9(2):24.
  51. Pollak M.N. Investigating metformin for cancer prevention and treatment: The end of the beginning. Cancer Discov. 2012;2:778-90.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2016

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>